The global maggot debridement market size was valued at USD 9.1 million in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 9.8% from 2020 to 2027. The global increase in the incidence of chronic diseases such as diabetes, cancer, and other autoimmune diseases is one of the major factors contributing to market growth.
According to the National Diabetes Statistic Report 2017, published by the CDC, more than 100.0 million people in the U.S. are living with diabetes or prediabetes. Furthermore, as per the International Diabetes Federation, the global prevalence of diabetes is expected to increase from 366.0 million in 2011 to 552.0 million by 2030. Since prolonged diabetes may lead to diabetic foot ulcers, the rising incidence of diabetes is expected to positively impact the growth of the market for maggot debridement. Loose larva and bio bags are the latest technology used in the treatment of diabetic foot ulcers, venous leg ulcers, and pressure ulcers.
Cancer has been a global healthcare burden as it is one of the leading causes of death. According to estimates by WHO, cancer is the leading cause of death globally and almost one in six deaths occur due to cancer. In addition, over 70.00% of cancer-related deaths occur in middle- and low-income countries. Owing to the rising prevalence of chronic conditions, the demand for maggot debridement therapy has also increased.
Increasing incidence of burns, trauma events, and road accidents across the globe is anticipated to drive the market for maggot debridement. For instance, according to WHO (2018), approximately 1,000,000 people in India suffer from severe or moderate burns every year. In addition, as per the NCBI, in 2017, countries such as Finland, the Netherlands, Bulgaria, China, Australia, and the U.K. reported a rise in the incidence of burn wounds.
Furthermore, according to the American Association for the Surgery of Trauma, in 2017, around 1.2 million people died globally, and road accidents account for around 3,242 deaths per day. Road accidents mostly occur in middle- or low-income countries. Biomaterials and skin substitutes are majorly used for healing all kinds of burn wounds. Thus, a rising number of accidents is expected to boost the demand for products, which is expected to lead to considerable growth in the market for maggot debridement over the forecast period.
The chronic wound segment held the largest revenue share of 60.2% in 2019 in the market for maggot debridement. The segment is anticipated to witness significant growth over the forecast period. Maggot debridement is majorly used in the treatment of chronic wounds. The chronic wounds comprise diabetic foot ulcers, venous leg ulcers, and pressure ulcers. The pressure ulcer segment is anticipated to witness the fastest growth rate over the forecast period. Pressure ulcers are also known as bed sores and usually occur due to prolonged intense pressure on the skin. Prolonged hospital stay is the most common cause of such ulcers. Pressure ulcers are common in the geriatric population. Pressure ulcers generally occur in the bony areas of the body such as ankles, hips, and tailbone. The rising geriatric population across the globe is a major factor driving the segment.
The acute wound segment is anticipated to witness the fastest growth in the market for maggot debridement over the forecast period. The acute wound comprises burns and other wounds. An increase in the number of burn injuries across the globe is a major factor driving the segment. Every year, around 50.0% of the population globally is at risk of fire-related traumas, of which 90.0% of the cases occur in moderate-to-low income countries. As per WHO, over 1,000,000 people are registered, annually, as moderately or severely burnt. Thus, the segment is expected to grow at a significant rate over the forecast period.
In 2019, the hospitals segment held the largest revenue share of 45.1%. This is owing to the increasing incidence of chronic wounds. In addition, the increasing incidence of diabetic foot ulcers and venous leg ulcers is among the major factors driving the segment. Moreover, increasing cases of surgical wounds due to a rise in the number of surgeries is also driving the segment. On the basis of end-use, the maggot debridement market is segmented into hospitals, clinics, wound care centers, and others.
The wound care centers segment is expected to witness the fastest growth in the market for maggot debridement over the forecast period. Most chronic wounds require a prolonged recovery period, leading to frequent changing of dressings. Thus, the demand for wound debridement products in wound care centers is increasing, as these institutions provide proper treatment for chronic and acute wounds. Moreover, the geriatric and bariatric population and patients suffering from chronic wounds prefer wound care centers over hospital stays, owing to the rising awareness regarding such institutions.
The biobags segment held the largest revenue share of around 76.3% in 2019 in the market for maggot debridement. The segment is anticipated to witness significant growth over the forecast period. This is owing to the rising prevalence of chronic wounds and an increasing number of surgeries across the globe. Biobags are comparatively safer to use and provide results in 28 days. It is the first contained biosurgical dressing approved by the Food and Drug Administration (FDA).
Loose larva wound debridement therapy is the traditional method. A dose of 5-8 larvae per/sq cm is applied directly to the wound and an external dressing is built to contain the larva to the treatment area. The entire therapy takes 14 days for wound debridement. However, as compared to biobags, the loose larva is not safe to use, which might restrain the segment’s growth in the market for maggot debridement over the forecast period.
North America dominated the market for maggot debridement in 2019 and is expected to witness a considerable growth rate of 9.8% over the forecast period. Increasing the incidence of sports injuries, the rising number of road accidents, and the presence of several key players in the region are some of the factors expected to drive the market growth. In addition, the presence of a highly developed healthcare infrastructure and favorable reimbursement policies are expected to propel the growth of the market for maggot debridement over the forecast period.
In the Asia Pacific, the market for maggot debridement is anticipated to witness the fastest growth during the forecast period. The presence of developing countries such as Japan, India, and China is anticipated to fuel the market growth in this region. In addition, the growing medical tourism industry in these countries is also contributing to the increasing demand for wound dressing products in this region. For instance, according to a report on Export Health Services by the Directorate-General of Commercial Intelligence and Statistics of India, in 2015-2016, India had 58,300 tourists on medical visas.
Key companies are stressing on research and development to develop technologically advanced products to gain a competitive edge. Maggot debridement therapy is the future technique of wound debridement and researchers are continuously developing various techniques for safer, quicker, and easier wound debridement therapies. Some of the prominent players in the maggot debridement market include:
BioMonde
Monarch Labs
Mega Pharma (Pvt) Ltd.
Report Attribute |
Details |
Market size value in 2020 |
USD 9.9 million |
Revenue forecast in 2027 |
USD 19.1 million |
Growth Rate |
CAGR of 9.8% from 2020 to 2027 |
Base year for estimation |
2019 |
Historical data |
2016 - 2018 |
Forecast period |
2020 - 2027 |
Quantitative units |
Revenue in USD million and CAGR from 2020 to 2027 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Administration, application, end-use, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Country scope |
The U.S.; Canada; The U.K.; Germany; Japan; China; Brazil; Mexico; South Africa; Saudi Arabia |
Key companies profiled |
BioMonde; Monarch Labs; Mega Pharma (Pvt) Ltd. |
Customization scope |
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2027. For the purpose of this study, Grand View Research has segmented the global maggot debridement market report on the basis of administration, application, end-use, and region:
Administration Outlook (Revenue, USD Million, 2016 - 2027)
Loose Larva
Biobags
Application Outlook (Revenue, USD Million, 2016 - 2027)
Chronic Wounds
Diabetic Foot Ulcers
Pressure Ulcers
Venous Leg Ulcers
Others
Acute Wounds
Surgical & Traumatic Wounds
Burn Wounds
End-use Outlook (Revenue, USD Million, 2016 - 2027)
Hospital
Clinics
Wound Care Centers
Others
Regional Outlook (Revenue, USD Million, 2016 - 2027)
North America
The U.S.
Canada
Europe
Germany
The U.K.
Asia Pacific
Japan
China
Latin America
Brazil
Mexico
Middle East & Africa
South Africa
Saudi Arabia
b. The global maggot debridement market size was estimated at USD 9.07 million in 2019 and is expected to reach USD 9.91 million in 2020.
b. The global maggot debridement market is expected to grow at a compound annual growth rate of 9.8% from 2020 to 2027 to reach USD 19.08 million by 2027.
b. North America dominated the maggot debridement market with a share of 47.39% in 2019. This is attributable to the increasing incidence of sports injuries, the rising number of road accidents, and the presence of several key players in the region.
b. Some key players operating in the maggot debridement market include BioMonde, Monarch Labs, and Mega Pharma (Pvt) Ltd.
b. Key factors that are driving the maggot debridement market growth include rising investment in research and development, growing prevalence of chronic diseases, and the increasing number of burn cases.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
ESOMAR & Great Work to Place Certified
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."